Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
Blood Advances|May 19, 2020
Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responsesAlak Manna, Timothy Kellett, Sonikpreet Aulakh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 2, 2013
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allograftingMohamed A Kharfan-Dabaja, Claudio Anasetti, Hugo F Fernandez, et al.
Transplantation and Cellular Therapy|August 15, 2022
Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell TherapyDasom Lee, Aryanna I Jordan, Meghan A Menges, et al.
Blood|April 20, 2010
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemiaPeter G Maslak, Tao Dao, Lee M Krug, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
European Journal of Haematology|January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapseRachel Hu, Wei Wei, Agrima Mian, et al.
Scientific Reports|October 11, 2019
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cellsTessa Knox, Eva Sahakian, Debarati Banik, et al.
American Journal of Hematology|February 15, 2016
Autoimmune diseases and myelodysplastic syndromesRami S Komrokji, Austin Kulasekararaj, Najla H Al Ali, et al.
Scientific Reports|April 18, 2019
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cellsTessa Knox, Eva Sahakian, Debarati Banik, et al.
Blood Cancer Journal|May 7, 2026
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigationsNatalia Timofeeva, Breana Herrera, Hitomi Fujiwara, et al.
Pageof 16